Common Contracts

SUPPLY AGREEMENT

Supply Agreement • February 27th, 2023 • Vaxcyte, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  Supply Agreement
• Filed
  February 27th, 2023
• Company
  Vaxcyte, Inc.
• Industry
  Biological products, (no disgnostic substances)

This SUPPLY AGREEMENT (“Supply Agreement”) is made as of May 29, 2018 (the “Effective Date”) by and between SutroVax, Inc., a Delaware corporation having principal offices at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”) and Sutro Biopharma, Inc., a Delaware corporation, having principal offices at 310 Utah Ave, Suite 150, South San Francisco, CA, 94080 (“Sutro”). SutroVax and Sutro may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.”

SUPPLY AGREEMENT

Supply Agreement • May 22nd, 2020 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • California

• Contract Type
  Supply Agreement
• Filed
  May 22nd, 2020
• Company
  Vaxcyte, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  California

This SUPPLY AGREEMENT (“Supply Agreement”) is made as of May 29, 2018 (the “Effective Date”) by and between SutroVax, Inc., a Delaware corporation having principal offices at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”) and Sutro Biopharma, Inc., a Delaware corporation, having principal offices at 310 Utah Ave, Suite 150, South San Francisco, CA, 94080 (“Sutro”). SutroVax and Sutro may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.”

SUPPLY AGREEMENT

Supply Agreement • October 11th, 2019 • SutroVax, Inc. • Biological products, (no disgnostic substances) • California

• Contract Type
  Supply Agreement
• Filed
  October 11th, 2019
• Company
  SutroVax, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  California

This SUPPLY AGREEMENT (“Supply Agreement”) is made as of May 29, 2018 (the “Effective Date”) by and between SutroVax, Inc., a Delaware corporation having principal offices at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”) and Sutro Biopharma, Inc., a Delaware corporation, having principal offices at 310 Utah Ave, Suite 150, South San Francisco, CA, 94080 (“Sutro”). SutroVax and Sutro may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.”